Related Experiment Videos
[Anti-phospholipid syndrome nephropathy]
Dominique Nochy1, Eric Daugas, Gary Hill
1Service d'Anatomie Pathologique, Hôpital Européen Georges-Pompidou, 20, rue Leblanc, 75908 Paris Cedex15. dominique.nochy@hop.egp.ap-hop-paris.fr
Annales De Medecine Interne
|May 15, 2003
Summary
Antiphospholipid syndrome nephropathy (APSN) involves kidney damage from blood clots in lupus patients. This study identified factors predicting APSN in systemic lupus erythematosus, aiding early diagnosis and treatment.
Area of Science:
- Nephrology
- Rheumatology
- Vascular Biology
Context:
- Antiphospholipid syndrome (APS) can cause kidney damage, known as APS nephropathy (APSN).
- APSN is characterized by vaso-occlusive lesions in intrarenal vessels, leading to ischemic atrophy.
- The presence and predictors of APSN in systemic lupus erythematosus (SLE) require further investigation.
Purpose:
- To investigate the occurrence of APS nephropathy (APSN) in patients with systemic lupus erythematosus (SLE).
- To identify potential biologic or clinical factors that predict the presence of APSN in SLE patients.
Summary:
- A retrospective study analyzed 114 lupus patients to assess for APS nephropathy (APSN).
- The study aimed to uncover predictive factors for APSN within the SLE cohort.
- Findings detail the specific vaso-occlusive and thrombotic lesions characteristic of APSN in the renal vasculature.
Impact:
- This research can improve the early detection of kidney involvement in lupus patients.
- Identifying predictive factors for APSN may lead to targeted interventions and improved patient outcomes.
- Understanding APSN in SLE contributes to the broader knowledge of autoimmune kidney diseases.